OBI-3424 vs Pediatric Preclinical model

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire Oct. 24, 2017, 05:00 AM TAIPEI, Taiwan, Oct. 24, 2017 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), announced that new data, for OBI-3424 in vivo efficacy against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL), will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania, USA, by Professor Richard B. Lock, PhD, Head of the Children's Cancer Institute's Leukemia Biology Program at the Lowy Cancer Research Centre in Sydney, Australia. The study was supported by National Cancer Institute (NCI) grants CA199222 & CA199000, and conducted by the NCI Pediatric Preclinical Testing Consortium.

Poster presentation time: Sunday, October 29, 2017, 12:30 p.m. – 3:00 p.m. EDT Title: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study Session Title: Late Breaking Poster Session B Abstract number: LB-B16Presenting author: Prof. Richard B. Lock, PhD, Head of the Children's Cancer Institute, Leukemia Biology Program, at the Lowy Cancer Research Centre, (Sydney, Australia) Location: Pennsylvania Convention Center, Hall E. Philadelphia, Pennsylvania, USA.

About OBI-3424 OBI-3424 is a first-in-class novel small-molecule prodrug that selectively targets cancers that overexpress the enzyme aldo-keto reductase 1c3 (AKR1C3), and selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme. This selective mode of activation distinguishes OBI-3424 from traditional alkylating agents, such as cyclophosphamide and ifosfamide, which are non-selective. AKR1C3 overexpression has been documented in a number of treatment-resistant and difficult to treat cancers including: hepatocellular carcinomas (HCC), castrate-resistant prostate cancer (CRPC) and T-cell acute lymphoblastic leukemia (T-ALL). Furthermore, individualized patient selection by staining for AKR1C3 overexpression by immunohistochemistry can be performed to identify patients with other tumor types most likely to respond to treatment with OBI-3424, offering the possibility for a streamlined clinical development strategy. OBI Pharma plans an Investigational New Drug (IND) application filing with the U.S. Food and Drug Administration (FDA) in early 2018.OBI Pharma has OBI-3424 worldwide rights with the exception of the following countries, of which Ascenta Pharma has rights: China, Hong Kong, Macao, Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey and India.

About OBI Pharma OBI Pharma, Inc. is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo series, AKR1C3, and other promising targets. The company's flagship product is Adagloxad Simolenin (formerly OBI-822), a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation immunotherapies for difficult to treat cancers, including lung, colorectal, pancreatic, gastric, and ovarian cancer. Additional information can be found at www.obipharma.com.